Albuterol sulfate tablets
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Sulfate Tablets: Efficacy, Safety, and Comparative Studies
Introduction to Albuterol Sulfate Tablets
Albuterol sulfate is a beta-2-adrenergic bronchodilator commonly used to relieve bronchospasm in conditions such as asthma. Available in various formulations, including tablets, syrup, and inhalers, albuterol sulfate is effective in both acute and chronic management of asthma symptoms.
Efficacy of Extended-Release Albuterol Sulfate Tablets in Children
Extended-release albuterol sulfate tablets have been shown to be effective in improving pulmonary function and reducing asthma symptoms in children aged 6 to 12 years. A study involving 157 patients demonstrated significant improvements in forced expiratory volume (FEV1) and reduced severity of asthma symptoms with no serious treatment-related adverse events reported . This suggests that extended-release albuterol tablets can be a viable option for pediatric asthma management.
Bioavailability and Pharmacokinetics of Albuterol Sulfate Tablets
The bioavailability of albuterol sulfate from tablet formulations is comparable to that from syrup formulations. A study involving 12 male volunteers found that the drug was rapidly absorbed, with maximum concentrations achieved within 1.8 to 2.0 hours. The elimination half-life ranged from 4.8 to 5.5 hours, indicating that the tablet form is as effective as the syrup form in delivering the drug .
Comparative Efficacy in Nocturnal Asthma
Extended-release albuterol sulfate tablets have been compared to long-acting inhaled salmeterol in treating nocturnal asthma. Both medications showed similar improvements in morning peak expiratory flow and reduced nighttime awakenings. However, there was no significant difference in the overall efficacy between the two treatments, suggesting that extended-release albuterol tablets are as effective as inhaled salmeterol for nocturnal asthma control .
Combination Therapy with Theophylline
In elderly patients with acute asthma, combining albuterol sulfate aerosol inhalation with theophylline tablets has shown superior efficacy compared to albuterol alone. This combination therapy resulted in better forced expiratory volume (FEV) and higher overall response rates, indicating that it can quickly alleviate bronchospasm and other asthma symptoms .
Development of Extended-Release Formulations
Research into the development of extended-release albuterol sulfate tablets has identified several potential polymers, including Kollidon SR and Hydroxypropylmethylcellulose (HPMC). These polymers help maintain the tablet's geometric shape and control the drug release, making them suitable candidates for extended-release formulations .
Safety and Tolerance in Pediatric Use
In a study involving asthmatic children aged 6 to 14 years, albuterol sulfate tablets were found to be effective and well-tolerated. The 4 mg dose was particularly effective, with the syrup formulation showing a slightly better profile in terms of pulmonary function improvement and duration of effect compared to tablets .
Conclusion
Albuterol sulfate tablets, particularly in extended-release formulations, offer a convenient and effective option for managing asthma in both children and adults. They provide comparable efficacy to other forms such as syrups and inhalers, with a favorable safety profile. Further research and development of extended-release formulations could enhance their utility in long-term asthma management.
Sources and full results
Most relevant research papers on this topic
Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
Extended-release albuterol tablets (4 mg) effectively improved pulmonary function and asthmatic symptoms in children aged 6-12 years, with no serious treatment-related adverse events.
DOI
Curative effect of albuterol sulfate aerosol inhalation and theophylline tablets among elderly patients with acute asthma
Albuterol sulfate aerosol inhalation combined with theophylline tablets effectively treats acute senile asthma with better safety and convenience compared to monotherapy.
Effect of Kollidon® SR on the release of Albuterol Sulphate from matrix tablets.
Kollidon SR and HPMC and Carbopol are potential candidates for extended release Albuterol Sulphate tablets, with Kollidon SR maintaining tablet shape and HPMC promoting drug release through diffusion.
DOI
Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma.
Both extended release albuterol tablets and inhaled salmeterol effectively control nocturnal asthma symptoms, with similar bronchodilation and reduced rescue albuterol use.
DOI